Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

WHO advise against international control of ketamine
Ketamine
Ketamine is often the only anaesthetic agent available in most developing countries and is also used for pain management.

Committee concludes medical benefits far outweigh potential harm 

Ketamine should not be placed under international control because it does not pose a threat to public health, the World Health Organisation has announced.

It is the fourth time since 2006 that the organisation has made the recommendation and follows a review of the latest evidence by the WHO Expert Committee on Drug Dependence.

The committee concluded that ketamine abuse does not pose a global public health threat, while controlling it could limit access to the only anaesthetic and pain killer available in large areas of the developing world.

“The medical benefits of ketamine far outweigh potential harm from recreational use,” said Marie-Paule Kieny, assistant-director general for health systems and innovation at WHO.

“Controlling ketamine internationally could limit access to essential and emergency surgery, which would constitute a public health crisis in countries where no affordable alternatives exist.”

Used in surgical and diagnostic procedures, ketamine is often the only anaesthetic agent available in most developing countries and is also used for pain management.

Ketamine has a great safety record, but recently it has also been used recreationally, prompting moves to control the substance under international law.

On each of these occasions - in 2006, 2012, 2014 and this year – the WHO Committee has recommended against scheduling. This and other recommendations of the Expert Committee will be conveyed to the Commission on Narcotic Drugs for its final decisions in March 2016.

“We have found that placing substances under international control can often limit access to them for medical purposes,” said Kees De Joncheere, WHO director for essential medicines and health products.

“Morphine is a case in point: even though it is inexpensive and one of the best substances available for pain management, in most countries availability and use are limited due to excessive regulation.”

Image (C) Psychonaught

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.